PLAY PODCASTS
Pure Global: Singapore AI MedTech - Navigating HSA's New High-Stakes Regulatory Maze.

Pure Global: Singapore AI MedTech - Navigating HSA's New High-Stakes Regulatory Maze.

ASEAN MedTech Insights · Ran Chen

March 16, 20261m 45s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

This week on ASEAN MedTech Insights, we dissect the groundbreaking new guidelines from Singapore's Health Sciences Authority (HSA) for AI-powered medical devices. As Singapore aims to become a global leader in health innovation, what do these stringent new rules mean for manufacturers and their path to market? We explore the critical shift from static validation to continuous lifecycle management for adaptive AI. This isn't just another regulatory update; it's a fundamental change in how AI safety, efficacy, and evolution are managed in one of Asia's most critical MedTech markets. Consider this scenario: Your company is ready to launch a revolutionary AI diagnostic tool in Singapore. Suddenly, you discover that your entire clinical validation and post-market strategy is obsolete under the HSA's new framework, which now demands a pre-approved plan for real-world performance monitoring. This could delay your launch by months and add significant unexpected costs to your budget. Key Questions This Episode Answers: * What specific changes must be made to a technical dossier to comply with the HSA's new AI guidelines? * How can you design a post-market surveillance plan for an AI that constantly learns and adapts? * What are the new cybersecurity and data governance requirements for AI medical devices in Singapore? * How does this new framework impact the cost and timeline for market entry? * What kind of real-world clinical data is the HSA now expecting for AI validation? * How can startups future-proof their AI device submissions against evolving regulations? * What are the hidden risks of failing to comply with these lifecycle management requirements? At Pure Global, we specialize in demystifying complex regulatory pathways. From AI-driven technical dossier preparation to developing robust post-market surveillance plans, our blend of local expertise and advanced data tools provides end-to-end solutions to get your MedTech innovation to market faster. Contact us for a strategic consultation at [email protected] or visit https://pureglobal.com/.